Analysts expect Telix Pharmaceuticals to report Q1 2026 revenue of US$230 million and an EPS of -US$0.01, while the current share price of A$14.21 remains well below the average analyst target of A$23.32. The primary narrative for investors is the company's regulatory progress, specifically the upcoming September 11 PDUFA date for Pixclara and the market expansion of its diagnostic portfolio.
Recent commercial performance has been strong, with unaudited first-quarter revenue growing 24% year-over-year driven by robust global uptake of Illuccix and the successful launch of Gozellix. Market participants are now shifting focus toward the clinical progress of the Phase III ProstACT Global study for TLX591, which represents Telix's transition into the large-scale therapeutic market.